【ChiCTR1900023491】Mindfulness-based intervention for children/youth with internalizing problems and their families: a pilot study
ChiCTR1900023491
正在进行
/
/
/
2019-05-31
/
/
children/youths with internalizing problems
Mindfulness-based intervention for children/youth with internalizing problems and their families: a pilot study
Mindfulness-based intervention for children/youth with internalizing problems and their families: a pilot study
The objective of this pilot study is to examine the feasibility and acceptability of a mindfulness-based interventional program for children/youth with internalizing problems and their parents in Hong Kong, using wait list control and a pre-post design
随机平行对照
探索性研究/预试验
The randomisation will be conducted by an experienced independent statistician using computer-generated random results.
Not stated
The D. H. Chen Foundation, Hong Kong SAR
/
25
/
2019-07-04
2021-07-03
/
1) anxious/depressed, withdrawn/depressed, and somatic complains as shown with a high score in the Child Behavior Checklist; 2) have not participated in mindfulness program before; 3) and at least one of their parents agrees to participate.；
请登录查看The exclusion criteria will be: (1) being unable to communicate and understand Chinese language as the intervention will be conducted in Chinese; (2) having a medical condition rendering him/her to be incapable to participate in the study; (3) unwilling or unable to give consent.；
请登录查看The D. H. Chen Foundation, Hong Kong SAR
/
The D. H. Chen Foundation, Hong Kong SAR的其他临床试验
- Mindfulness-based intervention for children/youth with internalizing problems and their families: a pilot study
- Mindfulness based intervention for Chinese children with autism and their parents: a randomised controlled trial
- A randomised controlled trial comparing MYmind with waitlist control among Chinese children with ADHD and their parents
香港中文大學賽馬會公共衛生與基層醫療學院的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04